Seeking Alpha

yzzycz

yzzycz
Send Message
View as an RSS Feed
View yzzycz's Comments BY TICKER:
Latest  |  Highest rated
  • BioLife Solutions Offers Diversified Exposure To Regenerative Medicine And 3-D Bio-Printing [View article]
    you have to understand the "larger competitors" are not interested in revenues like BLFS have now. For them 2M per Q is just pocket money. When time comes and BLFS revenue will increase by many many multiples at that point it will be already late for competitors to enter into space they know nothing about. Majority of "competitors" are just companies with home brew. Of course what can happen is a buyout at some point.
    Apr 17 10:17 AM | 1 Like Like |Link to Comment
  • BioLife Solutions Offers Diversified Exposure To Regenerative Medicine And 3-D Bio-Printing [View article]
    Don't forget about increasing client base. Also they can brake into blood storage/transplant transport markets.
    As for competition, right now their product is highly superior to anything out there. Look at 5 days storage compared with others. When Biolife still have close to 90% recovery the next best is the one with 7 resp 12%
    Apr 14 11:55 PM | 2 Likes Like |Link to Comment
  • BioLife Solutions Offers Diversified Exposure To Regenerative Medicine And 3-D Bio-Printing [View article]
    R/S and over 100% dilution to wipe out 16M debt and get up listed on Nasdaq CM. Very pain full for us long term holders but i just avg down. From now on there is nothing in their way anymore. With 9M in revenue with year over year 80% increase on AVG and huge potential in stem cell sector the MC of 42M is very low.
    Apr 14 11:46 PM | 1 Like Like |Link to Comment
  • BioLife Solutions Offers Diversified Exposure To Regenerative Medicine And 3-D Bio-Printing [View article]
    Good article. Waiting for ages on somebody to write about BLFS. Very undervalued stock with huge potential as they are the one who sells to all.
    "Whenever there's a gold rush the only folks who always get rich are those selling picks and shovels".
    Apr 14 03:46 PM | 2 Likes Like |Link to Comment
  • BioLife Solutions Offers Diversified Exposure To Regenerative Medicine And 3-D Bio-Printing [View article]
    Biolife does not do 3D printing. Read the article.
    Apr 14 03:45 PM | 3 Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Good job Biotech, as always. This guy have no idea about potential. That is what counts.
    Apr 7 04:14 PM | 8 Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    better job than yours. The positive results from IBD can push this stock well over $10. It would be confirmation of multistem and WS is never asleep. Possible income in billions would make this easily stock with 1-2B MC without IS results yet available. Stocks like KERX, ACAD or ONVO are just proof of it.
    Apr 7 04:12 PM | 9 Likes Like |Link to Comment
  • Weighing The Pros And Cons Of InVivo Therapeutics [View article]
    ok...now you are talking. I guess everyone is waiting for this one.
    Mar 26 03:23 PM | Likes Like |Link to Comment
  • Weighing The Pros And Cons Of InVivo Therapeutics [View article]
    you just manipulating what i said. You HAVE been taken off as analyst for NVIV. That is a fact. You are not the only one as chyten guy stated, that is also a fact. You pissed off NVIV management or not? I guess i don't have to answer that one..

    About your analysis. I actually agree on some points. Anyhow to say they will be out of money is kinda pointless. As you know that is the pain of almost every micro/small biotech out there.

    I would like to see management to step up and start to communicate with shareholders. That is for sure. Agree 100% on that one.

    Frank...story for a book.
    Mar 26 11:27 AM | Likes Like |Link to Comment
  • Weighing The Pros And Cons Of InVivo Therapeutics [View article]
    I can explain why Napodano is not welcomed at NVIV. Look at the chart, there is an explanation. He is also not the analyst covering this stock. He was taken off by Mr.Astrue. I have no idea from where this chyten guy get his info. The only official analyst is Aegis Capital/Raghuram Selvaraju.
    After Napodano previous piece stock plunged to $1. It is not known if that one was hit piece on purpose or not, anyhow i cannot blame NVIV management for they won't talk to him.
    Mar 23 08:39 PM | Likes Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    Yep...the scary part is the paid pumpers on Yahoo board. People think nothing of it...they think is some kinda invented legend. They are deadly wrong. Paid pumpers are just everywhere.
    Mar 13 11:09 AM | 2 Likes Like |Link to Comment
  • Best Short Idea In 2014: Organovo Holdings, Inc. [View article]
    That is some serious bash. Not saying you are not right on some points, but i can see longs going crazy. Can't wait to read reactions.
    Mar 11 08:51 AM | 3 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Hey Luis...and why would you care? Why would you care if ATHX doubles or triples? You just woke up or something? Pissed off you didn't get in at $2? Or you working for somebody who decided they want cheap shares? What a garbage your article is. ATHX MC of 240M is NOTHING.
    I would expect ATHX to have MC before something important like results for IBS at least 5x higher. MEsoblast is over 1B MC.
    See, i think ATHX is highly undervalued. The possible revenue if they succeed with IS is so big the MC of 20B would be considered as small.
    I think you are overvalued...but as i see everybody here thinks the same.
    Feb 25 09:55 PM | 4 Likes Like |Link to Comment
  • Athersys: Two Crucial Near-Term Events [View article]
    I invest just in Biotech. You can split risk. I have 2 high risk companies (ATHX is one of them) with highest amount of money, but to back this 2 guys i have another 40% of my portfolio in one small biotech with already 10M revenue and 2 small generic biotechs with MC of 50/80M, big pipeline and both partnered with PAR and some others. That guys are very low risk. They spend small money on research (just new delivery technology) and drugs are already FDA approved.
    Feb 19 07:30 PM | Likes Like |Link to Comment
  • New Cash To Help Drive Amarantus Pipeline [View article]
    I think AMBS will be a bad story.
    Feb 18 04:33 PM | Likes Like |Link to Comment
COMMENTS STATS
157 Comments
185 Likes